FinancialBuzz.com’s latest The Buzz Show: Featuring Our Corporate News Recap on “Vertex Down 20% After Discontinuing VX-814 Study”
Vertex Pharmaceuticals (NASDAQ: VRTX) is down more than 20% from previous close in early morning trading after axing its Phase 2 study of VX-814 Targeting Alpha-1 Antitrypsin Deficiency.
Based on the safety and pharmacokinetic profile of VX-814 observed in the trial, Vertex will discontinue development of the drug, while its continuing Phase 2 trials for the structurally distinct VX-864 , with results expected in the first half of 2021.
Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has multiple approved medicines that treat the underlying cause of cystic fibrosis (CF) — a rare, life-threatening genetic disease — and has several ongoing clinical and research programs in CF. Beyond CF, Vertex has a robust pipeline of investigational small molecule medicines in other serious diseases where it has deep insight into causal human biology, including pain, alpha-1 antitrypsin deficiency and APOL1-mediated kidney diseases. In addition, Vertex has a rapidly expanding pipeline of genetic and cell therapies for diseases such as sickle cell disease, beta thalassemia, Duchenne muscular dystrophy and type 1 diabetes mellitus.
For more information, please visit: Vertex Pharmaceuticals Incorporated
About The Buzz: A Financial Buzz Show on daily news, covering the most up to date financial information. The Buzz intends to provide factual and relevant information for its audience. The Buzz is 100% original content, created by Financial Buzz Media. Located on Wall Street in the heart of New York City’s financial district, FinancialBuzz.com is a credible source for the world’s latest trending financial and economic news. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content.